PROLOR Biotech To Present New Preclinical Data On Its Long-Acting Clotting Factor VIIa At Leading European Scientific

  PROLOR Biotech To Present New Preclinical Data On Its Long-Acting Clotting
            Factor VIIa At Leading European Scientific Conference

--New Data Demonstrate Potential for Long-Acting Subcutaneous Administration,
Potentially Allowing Hemophilia Patients to Self-Administer Factor Vlla-CTP at
Home Prophylactically--

PR Newswire

WARSAW, Poland and NES-ZIONA, Israel, Feb. 6, 2013

WARSAW, Poland and NES-ZIONA, Israel, Feb. 6, 2013 /PRNewswire/ --PROLOR
Biotech, Inc. (NYSE MKT: PBTH), today announced that the company will present
new data on its long-acting clotting factor VIIa (Factor Vlla-CTP) at the
Annual Congress of the European Association for Haemophilia and Allied
Disorders (EAHAD). PROLOR's Factor VIIa-CTP is a next-generation
investigational therapy currently in advanced preclinical development for the
potential treatment of patients with hemophilia.

Currently, factor VIIa therapy is available only as an intravenous (IV)
formulation, which can be onerous for patients. The company will present new
data at the EAHAD Congress showing that PROLOR's long-acting Factor VIIa-CTP
has demonstrated the potential for subcutaneous (SC) administration in
addition to standard IV dosing. PROLOR researchers believe that a long-acting
factor VIIa therapy that could be administered subcutaneously, using a simple
injection, would allow children and adults with hemophilia to easily
self-administer factor Vlla at home on a prophylactic basis, significantly
improving their quality of life.

Dr. Abraham Havron, CEO of PROLOR, commented, "We have previously presented
data in animal models of hemophilia showing that Factor Vlla-CTP demonstrated
superiority across key efficacy and safety parameters as compared to current
factor VIIa therapy. The potential for SC administration may represent a
major competitive advantage for our long-acting Factor Vlla-CTP, and we expect
to initiate a Phase II clinical trial in hemophilia patients in late 2013 or
early 2014."

The data will be presented from 5:00-8:00pm local time on February 6, 2013 by
Dr. Gili Hart, Director of Pre-Clinical Affairs at PROLOR and head of the
company's long-acting clotting factors program. The European Association for
Haemophilia and Allied Disorders 6^th Annual Congress is being held February
6-8, 2013 in Warsaw, Poland. For more information, visit:

About Hemophilia
Patients with hemophilia do not produce adequate amounts of the clotting
factors that are necessary for effective blood clotting. In severe
hemophiliacs even a minor injury can result in blood loss that may continue
for days or weeks, with the potential for debilitating permanent damage to
joints and other organs and premature death. According to the World Health
Organization, more than 400,000 people worldwide have hemophilia.
Commercially available recombinant clotting factors have enabled many
hemophiliacs to live near-normal lives, but frequent injections, infusions
and/or blood transfusions may be required.

PROLOR Biotech, Inc. is a clinical stage biopharmaceutical company applying
unique technologies, including patented CTP technology and its long-acting
reversible-pegylation technology, primarily to develop longer-acting
proprietary versions of already approved therapeutic proteins that currently
generate billions of dollars in annual global sales. The CTP technology is
applicable to virtually all proteins. PROLOR is developing a long-acting
version of human growth hormone, which successfully completed a Phase II
clinical trial. It also is developing long-acting versions of factor VIIa and
factor IX for hemophilia and a GLP-1/Glucagon dual receptor agonist peptide
for diabetes and obesity, all of which are in preclinical development. For
more information, visit

Safe Harbor Statement: This press release contains forward-looking
statements, which may be identified by words such as "expects," "plans,"
"projects," "will," "may," "anticipates," "believes," "should," "would",
"intends," "estimates," "suggests," "has the potential to" and other words of
similar meaning, including statements regarding the results of current
clinical studies and preclinical experiments and the effectiveness of PROLOR's
long-acting protein programs, which are made pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995. Investors
are cautioned that forward-looking statements involve risks and uncertainties
that may affect PROLOR's business and prospects, including the risks that
PROLOR may not succeed in generating any revenues or developing any commercial
products, including any long-acting versions of human growth hormone,
erythropoietin, interferon beta, GLP-1 and other products; that the
long-acting products in development may fail, may not achieve the expected
results or effectiveness and/or may not generate data that would support the
approval or marketing of these products for the indications being studied or
for other indications; that ongoing studies may not continue to show
substantial or any activity; that the actual dollar amount of any grants from
Israel's Office of the Chief Scientist is uncertain and is subject to policy
changes of the Israeli government, and that such grants may be insufficient to
assist with product development; and other risks and uncertainties that may
cause results to differ materially from those set forth in the forward-looking
statements. The results of clinical trials in humans may produce results that
differ significantly from the results of clinical and other trials in animals.
The results of early-stage trials may differ significantly from the results of
more developed, later-stage trials. The development of any products using the
CTP platform technology could also be affected by a number of other factors,
including unexpected safety, efficacy or manufacturing issues, additional time
requirements for data analyses and decision making, the impact of
pharmaceutical industry regulation, the impact of competitive products and
pricing and the impact of patents and other proprietary rights held by
competitors and other third parties. In addition to the risk factors
described above, investors should consider the economic, competitive,
governmental, technological and other factors discussed in PROLOR's filings
with the Securities and Exchange Commission. The forward-looking statements
contained in this press release speak only as of the date the statements were
made, and we do not undertake any obligation to update forward-looking
statements, except as required under applicable law.

PROLOR CONTACT:                       MEDIA CONTACT:
Shai Novik, President                   Barbara Lindheim
PROLOR Biotech, Inc.             BLL Partners, LLC
Tel: +1 866 644-7811                      +1 212 584-2276


Press spacebar to pause and continue. Press esc to stop.